SAB Biotherapeutics (SABS) Competitors

$3.90 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.74 -0.16 (-4.10%)

As of 05/22/2026 07:58 PM Eastern

SABS vs. IRWD, RIGL, XOMA, CBIO, and EBS

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Ironwood Pharmaceuticals (IRWD), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

SAB Biotherapeutics currently has a consensus target price of $11.00, indicating a potential upside of 182.05%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 59.01%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Ironwood Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A
Ironwood Pharmaceuticals	$296.15M	2.16	$24.02M	$0.60	6.53

SAB Biotherapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 10 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.95 beat SAB Biotherapeutics' score of 0.85 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 28.26% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -0.29% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

7.8% of SAB Biotherapeutics shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

SAB Biotherapeutics beats Ironwood Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

SAB Biotherapeutics currently has a consensus target price of $11.00, indicating a potential upside of 182.05%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 87.87%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

SAB Biotherapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, SAB Biotherapeutics had 6 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 6 mentions for Rigel Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 0.85 beat Rigel Pharmaceuticals' score of 0.16 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A
Rigel Pharmaceuticals	$294.28M	1.82	$367.02M	$18.72	1.55

Rigel Pharmaceuticals has a net margin of 121.50% compared to SAB Biotherapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Summary

Rigel Pharmaceuticals beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does SAB Biotherapeutics compare to XOMA Royalty?

SAB Biotherapeutics (NASDAQ:SABS) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

XOMA Royalty has a net margin of 53.46% compared to SAB Biotherapeutics' net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
XOMA Royalty	53.46%	12.56%	4.11%

XOMA Royalty has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A
XOMA Royalty	$52.15M	10.02	$31.71M	$1.57	26.53

SAB Biotherapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 8.9% of XOMA Royalty shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

SAB Biotherapeutics presently has a consensus price target of $11.00, indicating a potential upside of 182.05%. XOMA Royalty has a consensus price target of $53.75, indicating a potential upside of 29.05%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe SAB Biotherapeutics is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, SAB Biotherapeutics had 9 more articles in the media than XOMA Royalty. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 3 mentions for XOMA Royalty. SAB Biotherapeutics' average media sentiment score of 0.85 beat XOMA Royalty's score of 0.55 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA Royalty	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

XOMA Royalty beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 6 more articles in the media than Crescent Biopharma. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 6 mentions for Crescent Biopharma. SAB Biotherapeutics' average media sentiment score of 0.85 beat Crescent Biopharma's score of 0.60 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma currently has a consensus price target of $28.00, suggesting a potential upside of 35.00%. SAB Biotherapeutics has a consensus price target of $11.00, suggesting a potential upside of 182.05%. Given SAB Biotherapeutics' higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

SAB Biotherapeutics has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	52.73	-$153.94M	-$10.91	N/A
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A

SAB Biotherapeutics' return on equity of -0.29% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

SAB Biotherapeutics beats Crescent Biopharma on 11 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Emergent Biosolutions presently has a consensus target price of $12.00, suggesting a potential upside of 41.43%. SAB Biotherapeutics has a consensus target price of $11.00, suggesting a potential upside of 182.05%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Emergent Biosolutions has higher revenue and earnings than SAB Biotherapeutics. Emergent Biosolutions is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.59	$52.60M	-$0.28	N/A
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A

Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 10 more articles in the media than Emergent Biosolutions. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 2 mentions for Emergent Biosolutions. SAB Biotherapeutics' average media sentiment score of 0.85 beat Emergent Biosolutions' score of 0.23 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

SAB Biotherapeutics beats Emergent Biosolutions on 10 of the 17 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$298.21M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.85	18.74	21.22	25.66
Price / Sales	225.90	323.98	562.28	86.31
Price / Cash	11.41	125.17	43.49	56.67
Price / Book	1.31	7.09	10.31	7.14
Net Income	$13.27M	$24.45M	$3.57B	$335.98M
7 Day Performance	9.86%	6.38%	6.43%	4.15%
1 Month Performance	10.80%	2.43%	3.57%	2.54%
1 Year Performance	115.47%	62.98%	34.07%	35.06%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	3.9312 of 5 stars	$3.90 flat	$11.00 +182.1%	+115.5%	$298.21M	$1.32M	N/A	140
IRWD Ironwood Pharmaceuticals	3.4381 of 5 stars	$3.67 +4.9%	$6.23 +69.8%	+592.2%	$570.70M	$296.15M	6.12	220
RIGL Rigel Pharmaceuticals	2.9928 of 5 stars	$28.30 -1.1%	$54.50 +92.6%	+53.1%	$529.34M	$294.28M	1.51	160
XOMA XOMA Royalty	3.4372 of 5 stars	$41.54 -0.2%	$53.75 +29.4%	+67.6%	$522.21M	$52.15M	26.46	10
CBIO Crescent Biopharma	2.2501 of 5 stars	$18.48 -0.4%	$28.00 +51.5%	N/A	$511.18M	$10.84M	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. IRWD, RIGL, XOMA, CBIO, and EBS

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to XOMA Royalty?

Summary

How does SAB Biotherapeutics compare to Crescent Biopharma?

Summary

How does SAB Biotherapeutics compare to Emergent Biosolutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. IRWD, RIGL, XOMA, CBIO, and EBS

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Do analysts rate SABS or IRWD?

Which has better valuation and earnings, SABS or IRWD?

Which has more risk & volatility, SABS or IRWD?

Does the media favor SABS or IRWD?

Is SABS or IRWD more profitable?

Do institutionals & insiders believe in SABS or IRWD?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Do analysts rate SABS or RIGL?

Which has more risk and volatility, SABS or RIGL?

Does the media prefer SABS or RIGL?

Do insiders and institutionals have more ownership in SABS or RIGL?

Which has stronger earnings and valuation, SABS or RIGL?

Is SABS or RIGL more profitable?

Summary

How does SAB Biotherapeutics compare to XOMA Royalty?

Is SABS or XOMA more profitable?

Which has higher valuation and earnings, SABS or XOMA?

Which has more volatility and risk, SABS or XOMA?

Do insiders & institutionals have more ownership in SABS or XOMA?

Do analysts rate SABS or XOMA?

Does the media prefer SABS or XOMA?

Summary

How does SAB Biotherapeutics compare to Crescent Biopharma?

Do insiders and institutionals have more ownership in CBIO or SABS?

Which has more risk & volatility, CBIO or SABS?

Does the media favor CBIO or SABS?

Do analysts prefer CBIO or SABS?

Which has better earnings & valuation, CBIO or SABS?

Is CBIO or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to Emergent Biosolutions?

Do analysts prefer EBS or SABS?

Do insiders & institutionals have more ownership in EBS or SABS?

Which has higher valuation & earnings, EBS or SABS?

Which has more volatility & risk, EBS or SABS?

Does the media favor EBS or SABS?

Is EBS or SABS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools